Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia

Neoplasma. 1996;43(5):321-5.

Abstract

Hairy cell leukemia is a chronic lymphoproliferative disorder of B-cell lineage. Malignant cells express the interleukin-2 receptor (IL-2R) which is released in vitro as well as in vivo. The sera of patients with hairy cell leukemia contain elevated levels of this soluble receptor (sIL-2R). Sera of 24 patients with hairy cell leukemia were tested for sIL-2R. In 9 patients treated with 2-chlorodeoxyadenosine an improved clinical status was associated with decreasing serum sIL-2R. The maximal rate of decrease of sIL-2R level was observed within the second and the third week after the therapy initiation. Patients with disease progression had an increase in serum sIL-2R level. Our results suggest that serial measurement of sIL-2R level can be used as a reliable, noninvasive means to assess the disease activity and its response to therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / blood*
  • Cladribine / therapeutic use
  • Cohort Studies
  • Female
  • Humans
  • Leukemia, Hairy Cell / blood*
  • Leukemia, Hairy Cell / drug therapy
  • Male
  • Middle Aged
  • Receptors, Interleukin-2 / blood*
  • Receptors, Interleukin-2 / drug effects

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Receptors, Interleukin-2
  • Cladribine